Omicron variant-specific vaccine

Samsung Electronics Co. Vice Chairman Jay Y. Lee has met with biopharmaceutical conglomerate Moderna’s co-founder and telecommunications g...

Jay Y. Lee, vice chairman and de facto leader of South Korea’s top conglomerate Samsung, has embarked on a business trip to North America to f...

Moderna Inc.’s COVID-19 vaccine first produced by Samsung Biologics Co. under a contract manufacturing organization (CMO) service will be avai...

WASHINGTON D.C. -- US-based biotechnology company Moderna Inc. wasn’t a household name until the beginning of last year, when its fate changed...

Earlier this month, Singapore reached a Covid-19 milestone: The fully vaccinated portion of the population crossed 80%. But instead of moving ahead wi...

South Korea’s Samsung Biologics Co. is gearing up for the drug substance (DS) sector of the messenger ribonucleic acid (mRNA)-based COVID-19 v...

South Korean government will spend 6.3 trillion won ($5.4 billion) next year in supporting the state-designated Big 3 industries: future vehicles, n...

South Korea's electronics and auto industries, the two main pillars of Asia’s fourth-largest economy, are losing growth momentum. Demand is sl...

Shares in global carmakers such as Hyundai Motor Co. and Toyota Motor Corp. are tumbling. The automotive chip shortage is expected to deteriorate fu...

SK Bioscience Co. has received approval from South Korea’s Ministry of Food and Drug Safety (MFDS) for phase 3 clinical trials of its COVID-19...

The South Korean government will invest 2.2 trillion won ($1.9 billion) by 2025 to become a top five vaccine producer in the world. President Moon J...

As concerns rise over a resurgence of the COVID-19 pandemic, the war for talent in South Korea’s pharmaceutical industry is intensifying as th...

South Korea’s Samsung Biologics Co. posted its highest quarterly revenue and operating profit, thanks largely to a number of long-term manufac...

South Korean companies with low credit ratings around BBB are suffering weaker demand in the primary market. A spread in the Delta coronavirus varia...

Korea’s low-cost carriers (LCCs) are projected to post another period of financial loss in the second quarter of 2021.According to analyst est...

Celltrion Inc. on July 13 said that its COVID-19 treatment Regkirona has proven effective in reducing the incidence of severe cases of the virus by ...

Global stock markets lost ground on mounting fears over the spread of the Delta coronavirus variant. Record-breaking US shares riding on the hopes...

Federal Reserve Chair Jerome Powell and Bank of Korea (BOK) Governor Lee Ju-yeol will meet during a Group of 20 (G20) gathering of finance ministe...

South Korea will develop its own messenger ribonucleic acid (mRNA) vaccines by next year with plans to annually manufacture 100 million doses from 2...

German biopharmaceutical company CureVac N.V. may choose South Korea as one of its global production bases for the COVID-19 vaccine following Korean...

South Korea’s central bank governor on Friday flagged a tighter monetary policy for the second time in less than a month, fueling expectations...

Samsung Electronics Co., the bellwether of South Korea’s main bourse, has returned as the market darling, with foreigners buying heavily on th...

SK Bioscience Co. has secured additional funding for phase III clinical trial of GBP510, its COVID-19 vaccine candidate jointly developed with the I...

Samsung Biologics Co. will be manufacturing the US company Moderna’s COVID-19 vaccine (mRNA-1273) from the second half of this year in Korea. ...

South Korea’s Samsung Biologics Co. is in talks with Pfizer Inc.to produce the US drugmaker’s COVID-19 vaccine under a contract manufact...

South Korea’s biosimilar and pharmaceutical companies are looking at a growing chance of emerging as a global hub for manufacturing vaccines f...

Genexine Inc., one of the five South Korean pharmaceutical companies whose COVID-19 vaccine candidates have entered clinical trials, will export its...

South Korea’s SK Bioscience Co. is suspending production of SKYCellflu, an influenza vaccine, to focus on manufacturing COVID-19 vaccines inst...

South Korea’s pharmaceutical company Green Cross Corporation (GC) is holding a series of close meetings on contract manufacturing of Russia&rs...

South Korea’s SK Bioscience Co. is looking to post 1 trillion won ($900 million) in annual revenue from its vaccine business as the biopharmac...